Type 1.5 diabetes is an autoimmune form of diabetes that develops in adulthood and progresses slowly, often over months or years. Its formal name is latent autoimmune diabetes in adults, or LADA. It shares features with both type 1 and type 2 diabetes, which is exactly why it earns the “1.5” nickname and why it’s so frequently misdiagnosed. An estimated 4% to 14% of all people diagnosed with type 2 diabetes may actually have LADA instead.
How It Differs From Type 1 and Type 2
Like type 1 diabetes, LADA is driven by the immune system attacking the insulin-producing cells (beta cells) in the pancreas. Immune cells infiltrate the pancreas, gradually destroying its ability to make insulin. The key difference is speed. In classic type 1, this destruction happens quickly, often over weeks, and typically strikes in childhood or adolescence. In LADA, the autoimmune attack is milder and slower. Beta cell function declines gradually, and most people don’t need insulin for at least six months after symptoms appear. Many go years before oral medications stop working.
What makes LADA confusing is that it initially looks like type 2 diabetes. It appears in adults, blood sugar rises moderately, and the person can often manage at first without insulin. But unlike type 2, the underlying problem isn’t insulin resistance alone. The pancreas is actively being damaged by the immune system, which means it will eventually stop producing enough insulin no matter what lifestyle changes or oral medications are used.
Why It Gets Misdiagnosed So Often
Because LADA shows up in adults and progresses slowly, most people who have it are initially told they have type 2 diabetes. The early symptoms are identical: increased thirst, frequent urination, fatigue, and elevated blood sugar. A doctor seeing an adult with those symptoms will reasonably reach for a type 2 diagnosis, especially if the patient is overweight or has a family history of diabetes.
The misdiagnosis matters because the treatment paths are different. People with LADA who are treated as though they have type 2 diabetes may be prescribed medications that don’t address the real problem and, in some cases, can make things worse. A common class of type 2 medications called sulfonylureas works by forcing the pancreas to release more insulin. In someone with LADA, the beta cells are already under immune attack. Pushing them harder can accelerate their decline and increases the risk of dangerous blood sugar drops, especially if insulin is eventually added.
How Doctors Confirm the Diagnosis
Two blood tests are central to identifying LADA. The first is a GAD antibodies test, which looks for autoantibodies targeting an enzyme called glutamic acid decarboxylase. Finding these autoantibodies in an adult with diabetes is strong evidence that the immune system is attacking the pancreas, pointing toward LADA rather than type 2.
The second is a C-peptide test. C-peptide is a molecule released alongside insulin, so measuring it tells your doctor how much insulin your pancreas is actually producing. In type 2 diabetes, C-peptide levels are often normal or even high early on because the pancreas is working overtime to overcome insulin resistance. In LADA, C-peptide levels tend to be lower and decline over time as beta cells are destroyed. Together, these two tests paint a clear picture: autoantibodies confirm the immune component, and C-peptide tracks how much pancreatic function remains.
The challenge is that most doctors don’t order these tests routinely for adult-onset diabetes. If your blood sugar doesn’t respond well to typical type 2 treatments, or if you’re losing weight unexpectedly, those are signals worth investigating further.
What Happens Inside the Pancreas
The autoimmune process in LADA is driven primarily by T cells, a type of immune cell. Pancreatic biopsies from people with LADA show T cells infiltrating the islets, the clusters of cells in the pancreas responsible for making insulin. This is the most direct evidence that LADA is a cell-mediated autoimmune disease, similar in mechanism to type 1.
Part of the problem is a shortage of regulatory T cells, which normally act as brakes on the immune system. When these cells are reduced in number or don’t function properly, the immune system loses its ability to distinguish “self” from “threat” and begins attacking healthy tissue. B cells also play a role by producing the autoantibodies that serve as diagnostic markers and by activating other immune cells that carry out the actual destruction.
The slower pace of this attack compared to type 1 diabetes creates what researchers describe as a wider window for intervention. Because beta cells aren’t destroyed all at once, there’s time to adjust treatment to preserve whatever insulin production remains.
The Genetic Connection
LADA shares some genetic risk factors with type 1 diabetes, but the overlap is incomplete. Both conditions are associated with certain variations in the HLA gene region, which governs how the immune system identifies threats. However, the strongest genetic risk factors for type 1 are either absent or carry only about half the risk in LADA. A large study comparing the two conditions found that the frequency of high-risk genetic variants was significantly lower in LADA patients (about 38%) than in type 1 patients (about 59%). Meanwhile, genetic variants that protect against type 1 were nearly three times more common in people with LADA.
This genetic middle ground helps explain why LADA behaves like a hybrid. The immune attack is real but genetically “softer,” leading to slower progression and a clinical picture that overlaps with both type 1 and type 2.
Treatment and the Path to Insulin
There is no universal consensus on exactly how to manage LADA, but the overarching goal is to protect remaining beta cells and control blood sugar without accelerating immune damage. Early in the course of the disease, some people can manage with lifestyle changes and certain oral medications that don’t stress the pancreas. As beta cell function declines, insulin becomes necessary.
The timeline to insulin dependence varies widely. Some people need insulin within a year of diagnosis; others maintain partial pancreatic function for a decade or more. Factors that influence the speed of progression include age at onset, body weight, genetic background, and the intensity of the autoimmune response. Younger onset and the presence of multiple autoantibodies tend to predict faster progression.
Starting insulin earlier rather than later is a strategy some clinicians favor for LADA specifically. The reasoning is that giving the pancreas external help reduces the workload on surviving beta cells, potentially slowing their destruction. This is fundamentally different from the type 2 approach, where insulin is typically a last resort after oral medications fail. It’s one of the clearest examples of why getting the diagnosis right matters: the same disease treated under the wrong label can lead to years of suboptimal care.
Living With LADA
Day to day, managing LADA looks increasingly like managing type 1 diabetes as the condition progresses. That means monitoring blood sugar regularly, adjusting insulin doses, and paying attention to how food, exercise, and stress affect glucose levels. Early on, when some pancreatic function remains, blood sugar may be easier to control and less volatile. As insulin production drops, tighter management becomes necessary.
The emotional side is worth acknowledging. Many people with LADA spend months or years believing they have type 2 diabetes, trying medications that don’t work well, and feeling frustrated by unexplained blood sugar swings. Getting the correct diagnosis can be a turning point, not because the disease changes, but because the treatment finally matches what’s actually happening in the body.